AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial

Phase 2positiveABBV-466SkyriziPositive

AI Analysis

Summary

AbbVie announced that ABBV-466, a Skyrizi-based combination therapy, outperformed Skyrizi alone in a mid-stage trial in Crohn's disease. The article excerpt does not specify the combination partner, endpoint details, or patient numbers.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Skyrizi-based combination therapy ABBV-466 performed better than Skyrizi alone in a mid-stage Crohn's disease trial.

Importance:7/10

Sentiment:

0.60

Crohn's diseaseinflammatory bowel diseasePhase 2combination therapyIL-23Skyriziimmunology

Related Companies

$ABBV

Read the original article

Published by Endpoints News on October 19, 2026 12:51 PM

Read Original